Chun Loo Gan1, Shaan Dudani1, J Connor Wells1, Frede Donskov2, Sumanta K Pal3, Nazli Dizman3, Nityam Rathi4, Benoit Beuselinck5, Flora Yan6, Aly-Khan A Lalani7, Aaron Hansen8, Bernadett Szabados9, Guillermo de Velasco10, Ben Tran11,12, Jae Lyun Lee13, Ulka N Vaishampayan14, Georg A Bjarnason15, Mathushan Subasri16, Toni K Choueiri17, Daniel Y C Heng1. 1. Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. 2. Aarhus University Hospital, Aarhus, Denmark. 3. City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 4. Huntsman Cancer Hospital, Salt Lake City, UT, USA. 5. University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. 6. University of Texas Southwestern Medical Center, Dallas, TX, USA. 7. Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. 8. Princess Margaret Cancer Centre, Toronto, ON, Canada. 9. Queen Mary University of London, Barts Cancer Institute, London, UK. 10. University Hospital 12 de Octubre, Madrid, Spain. 11. Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Vic, Australia. 12. Peter MacCallum Cancer Center, Parkville, Vic, Australia. 13. Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 14. Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA. 15. Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. 16. London Ontario Health Sciences Centre, London, ON, Canada. 17. Dana-Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real-world effectiveness and dosing patterns of cabozantinib are not well characterized. METHODS: Patients with mRCC treated with cabozantinib between 2011 and 2019 were identified and stratified using the International mRCC Database Consortium (IMDC) risk groups. First- (1L), second- (2L), third- (3L), and fourth-line (4L) overall response rate (ORR), time to treatment failure (TTF), and overall survival (OS) were analyzed. Dose reduction rates and their association with TTF and OS were determined. RESULTS: A total of 413 patients were identified. The ORRs across 1L to 4L were 32%, 26%, 25%, and 29%, respectively, and the median TTF rates were 8.3, 7.3, 7.0, and 8.0 months, respectively. The median OS (mOS) rates in 1L to 4L were 30.7, 17.8, 12.6, and 14.9 months, respectively. For patients treated with 1L PD(L)1 combination agent (n = 31), 2L cabozantinib had ORR of 22%, median TTF of 5.4 months, and mOS of 17.4 months. About 50% (129/258) of patients required dose reductions. The TTF and mOS were significantly longer for patients who required dose reduction vs. patients who did not, with an adjusted hazard ratio of 0.37 (95% CI 0.202-0.672, p < 0.01) and 0.46 (95% CI 0.215-0.980, p = 0.04), respectively. Limitations include the retrospective study design and the lack of central radiology review. CONCLUSION: The ORR and TTF of cabozantinib were maintained from the 1L to 4L settings. Dose reductions due to toxicity were associated with improved TTF and OS. Cabozantinib has clinical activity after 1L Immuno-oncology combination agents.
BACKGROUND:Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real-world effectiveness and dosing patterns of cabozantinib are not well characterized. METHODS:Patients with mRCC treated with cabozantinib between 2011 and 2019 were identified and stratified using the International mRCC Database Consortium (IMDC) risk groups. First- (1L), second- (2L), third- (3L), and fourth-line (4L) overall response rate (ORR), time to treatment failure (TTF), and overall survival (OS) were analyzed. Dose reduction rates and their association with TTF and OS were determined. RESULTS: A total of 413 patients were identified. The ORRs across 1L to 4L were 32%, 26%, 25%, and 29%, respectively, and the median TTF rates were 8.3, 7.3, 7.0, and 8.0 months, respectively. The median OS (mOS) rates in 1L to 4L were 30.7, 17.8, 12.6, and 14.9 months, respectively. For patients treated with 1L PD(L)1 combination agent (n = 31), 2L cabozantinib had ORR of 22%, median TTF of 5.4 months, and mOS of 17.4 months. About 50% (129/258) of patients required dose reductions. The TTF and mOS were significantly longer for patients who required dose reduction vs. patients who did not, with an adjusted hazard ratio of 0.37 (95% CI 0.202-0.672, p < 0.01) and 0.46 (95% CI 0.215-0.980, p = 0.04), respectively. Limitations include the retrospective study design and the lack of central radiology review. CONCLUSION: The ORR and TTF of cabozantinib were maintained from the 1L to 4L settings. Dose reductions due to toxicity were associated with improved TTF and OS. Cabozantinib has clinical activity after 1L Immuno-oncology combination agents.
Authors: Moshe C Ornstein; Sumanta K Pal; Laura S Wood; Jackie M Tomer; Brian P Hobbs; Xuefei S Jia; Kimberly D Allman; Allison Martin; Thomas Olencki; Nancy B Davis; Timothy D Gilligan; Amir Mortazavi; W Kimryn Rathmell; Jorge A Garcia; Brian I Rini Journal: Lancet Oncol Date: 2019-08-16 Impact factor: 41.316
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Nizar M Tannir; Paul N Mainwaring; Brian I Rini; Hans J Hammers; Frede Donskov; Bruce J Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y C Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N Sternberg; David F McDermott; Dana T Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E Hutson; Sumanta Pal; Robert J Motzer Journal: Lancet Oncol Date: 2016-06-05 Impact factor: 41.316
Authors: Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles Journal: N Engl J Med Date: 2019-02-16 Impact factor: 91.245
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Brian I Rini; May Garrett; Bill Poland; Janice P Dutcher; Olivier Rixe; George Wilding; Walter M Stadler; Yazdi K Pithavala; Sinil Kim; Jamal Tarazi; Robert J Motzer Journal: J Clin Pharmacol Date: 2013-03-28 Impact factor: 3.126
Authors: Frede Donskov; M Dror Michaelson; Igor Puzanov; Mellar P Davis; Georg A Bjarnason; Robert J Motzer; David Goldstein; Xun Lin; Darrel P Cohen; Robin Wiltshire; Brian I Rini Journal: Br J Cancer Date: 2015-10-22 Impact factor: 7.640
Authors: Stefanie D Krens; Nielka P van Erp; Stefanie L Groenland; Dirk Jan A R Moes; Sasja F Mulder; Ingrid M E Desar; Tom van der Hulle; Neeltje Steeghs; Carla M L van Herpen Journal: BMC Cancer Date: 2022-03-02 Impact factor: 4.430
Authors: Giandomenico Roviello; Elisabetta Gambale; Roberta Giorgione; Daniele Santini; Marco Stellato; Giuseppe Fornarini; Sara Elena Rebuzzi; Umberto Basso; Davide Bimbatti; Laura Doni; Gabriella Nesi; Melissa Bersanelli; Sebastiano Buti; Ugo De Giorgi; Luca Galli; Andrea Sbrana; Raffaele Conca; Claudia Carella; Emanuele Naglieri; Sandro Pignata; Giuseppe Procopio; Lorenzo Antonuzzo Journal: Cancer Med Date: 2022-03-20 Impact factor: 4.711